Render Target: SSR
Render Timestamp: 2024-09-21T01:02:43.015Z
Commit: c4b931215f8ed52e59fa950853eadce9550a8bd5
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Mismatch Repair Antibody Sampler Kit #9786

This product is discontinued

Inquiry Info. # 9786

Please see our recommended alternatives.

    Product Information

    Product Description

    Mismatch Repair Antibody Sampler Kit provides an economical means to investigate the DNA mismatch repair system within the cell. The kit contains primary and secondary antibodies to perform four western blots with each antibody.

    Specificity / Sensitivity

    MLH1 (4C9C7) Mouse mAb detects endogenous levels of total MLH1 protein. MSH2 (D24B5) XP® Rabbit mAb detects endogenous levels of total MSH2 protein. MSH6 (L990) Antibody detects endogenous levels of total MSH6 protein.

    Source / Purification

    Monoclonal antibodies are produced by immunizing animals with truncated recombinant MBP-MLH1 or by immunizing animals with a synthetic peptide corresponding to residues at the amino terminus of human MSH2. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MLH6 protein. Antibodies are purified using protein A and peptide affinity chromatography.

    Background

    The DNA mismatch repair system (MMR) repairs post-replication DNA, inhibits recombination between nonidentical DNA sequences, and induces both checkpoint and apoptotic responses following certain types of DNA damage (1). MSH2 (MutS homologue 2) forms the hMutS-α dimer with MSH6 and is an essential component of the mismatch repair process. hMutS-α is part of the BRCA1-associated surveillance complex (BASC), a complex that also contains BRCA1, MLH1, ATM, BLM, PMS2 proteins, and the Rad50-Mre11-NBS1 complex (2). Mutations in MSH6 and other MMR proteins have been found in a large proportion of hereditary nonpolyposis colorectal cancer (Lynch Syndrome), the most common form of inherited colorectal cancer in the Western world (3). Mutations in MSH6 have been shown to occur in glioblastoma in response to temozolomide therapy and to promote temozolomide resistance (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.